Integra LifeSciences Holdings Corporation — Q1 2023 Form 10-Q Summary
Business context and reporting period
Integra develops and sells medical technologies through two reportable segments: Codman Specialty Surgical, focused on neurosurgical products and surgical instruments, and Tissue Technologies, focused on wound care, surgical reconstruction, and peripheral nerve repair. The filing covers the three months ended March 31, 2023, compared with the same period in 2022. The financial statements are unaudited and prepared under U.S. GAAP.
Key financial metrics
| Metric | Q1 2023 | Q1 2022 | Change |
|---|---|---|---|
| Revenue | $380.8 million | $376.6 million | +1.1% |
| Gross profit | $232.9 million | $234.1 million | -0.5% |
| Gross margin | 61.1% | 62.1% | -100 bps |
| Operating income | $36.4 million | $46.2 million | -21.2% |
| Operating margin | 9.6% | 12.3% | -270 bps |
| Net income | $24.2 million | $32.9 million | -26.2% |
| Diluted EPS | $0.29 | $0.39 | -25.6% |
| Operating cash flow | $26.2 million | $44.3 million | -41.0% |
Revenue was $248.1 million in Codman Specialty Surgical and $132.7 million in Tissue Technologies. U.S. revenue increased to $271.0 million, while Europe declined to $41.1 million. Asia Pacific revenue increased to $50.5 million.
Cash and cash equivalents were $307.4 million at March 31, 2023, compared with $456.7 million at December 31, 2022. Working capital was $747.2 million, down from $840.6 million at year-end. Capital expenditures were $13.7 million, resulting in approximately $12.5 million of quarterly free cash flow before financing and other considerations.
Total borrowings were approximately $1.44 billion, consisting primarily of $775.0 million under the term loan, $102.5 million under the securitization facility, and $575.0 million principal amount of convertible notes. Operating lease liabilities totaled $171.7 million. The company had no revolving credit borrowings and was in compliance with its debt covenants.
Material changes versus the prior comparable period
- Revenue increased modestly, despite a $7.0 million unfavorable foreign exchange impact and a $4.5 million revenue reduction related to the prior-year divestiture of the traditional wound care business.
- Tissue Technologies revenue increased 2.6%, including $1.8 million from the Surgical Innovation Associates acquisition. Excluding divestiture, acquisition, and foreign exchange effects, Tissue Technologies grew at a mid-single-digit rate.
- Gross margin declined because of unfavorable product mix and higher manufacturing costs.
- Research and development expense increased $2.6 million, and selling, general and administrative expense increased $6.7 million, primarily due to the SIA acquisition, new product development, clinical studies, consulting, and higher selling costs.
- Special charges increased to $24.5 million from $16.4 million. Q1 2023 charges included $8.8 million of acquisition, divestiture, and integration-related charges, $4.3 million of structural optimization charges, and $11.4 million related to European medical device regulation.
- Operating cash flow declined primarily because of lower earnings and working-capital usage, including a $25.4 million inventory increase and reductions in accrued liabilities.
- The company repurchased $150.0 million of stock under a 2023 accelerated share repurchase agreement and received 2.1 million shares initially. The remaining transactions were expected to be completed in Q2 2023.
Guidance, outlook, risks, and unusual items
The filing does not provide clear quantitative full-year revenue or earnings guidance. Management stated that sales and earnings were forecast to be sufficient to maintain compliance with the amended financial covenants over the following twelve months and that cash and available borrowings were sufficient to finance operations and capital expenditures for the foreseeable future.
- On March 24, 2023, the senior credit facility was amended and extended to March 24, 2028. LIBOR-based terms were replaced with SOFR-based terms, and the facility provides approximately $2.1 billion of aggregate capacity.
- The company continues to manage interest-rate and foreign-currency exposure through derivatives. Interest-rate swaps had $1.5 billion of notional amount at March 31, 2023.
- All CereLink intracranial pressure monitors remained subject to a voluntary global product removal initiated in August 2022 because of potentially out-of-range pressure readings. The company recorded an additional $0.8 million provision for product returns in Q1 2023 and no additional rework costs.
- The FDA commenced another inspection of the TEI Boston facility on March 1, 2023. The facility remains subject to a prior FDA Warning Letter and a 2021 Form 483 concerning quality-system matters. Products manufactured there represented approximately 4.4% of Q1 2023 consolidated revenue, and unresolved matters could lead to additional regulatory action.
- The SIA acquisition includes potential contingent payments of up to $90.0 million based on revenue milestones and FDA approval of DuraSorb. The recorded SIA contingent consideration liability was $61.2 million at March 31, 2023.
- Operating results may be affected by supply-chain constraints, inflation, foreign exchange, regulatory approvals, product acceptance, litigation, tax changes, acquisitions, integration activities, and competition. Management reported no material changes to the risk factors included in the 2022 Form 10-K.
- The 2025 convertible notes have a $575.0 million principal amount and mature August 15, 2025. The notes were classified as long term at March 31, 2023.
Important facts for investors to verify
- Whether the CereLink remediation and regulatory review permit product shipments to resume, and whether additional returns, rework, or revenue provisions are required.
- The outcome of the FDA inspection and remediation efforts at the TEI Boston facility.
- Progress toward DuraSorb FDA approval, related revenue milestones, and potential contingent consideration payments.
- Whether gross-margin pressure from product mix and manufacturing costs persists.
- Inventory levels, working-capital conversion, and operating cash flow following the Q1 increase in inventories.
- Interest-rate exposure under SOFR-based debt, including the effect of the 2025 maturity and future debt repayments.
- Completion and final settlement of the 2023 accelerated share repurchase agreement.